Rebecca Jansen, MD
Dermatology · Grand Rapids, MINPI 1548587801
Payments from drug & device makers
Across 33 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$228
- Lilly USA, LLC$161
- Amgen$61
- Pfizer$32
- Kyowa Kirin, Inc.$29
- Dermavant Sciences, Inc.$16
- plus $85 from 6 others
What the payments were for
- Food & beverage$612100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 11 | $228 |
| Lilly USA, LLC | 8 | $161 |
| Amgen | 3 | $61 |
| Pfizer | 2 | $32 |
| Kyowa Kirin, Inc. | 2 | $29 |
| Dermavant Sciences, Inc. | 1 | $16 |
| Arcutis Biotherapeutics, Inc. | 1 | $15 |
| Biofrontera Inc. | 1 | $15 |
| LEO Pharma Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Sun Pharmaceutical Industries Inc. | 1 | $14 |
| Sanofi | 1 | $11 |
How this compares
$612 in reported general payments places this provider in the 25th percentile of 404 dermatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 16 | $321,821 |
| Dupixent PenDupilumab | 59 | $233,501 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 27 | $183,391 |
| Humira(Cf) PenAdalimumab | 18 | $158,698 |
| Taltz SyringeIxekizumab | 11 | $74,910 |
| Fluorouracil | 359 | $21,353 |
| Clobetasol Propionate | 306 | $6,792 |
| Triamcinolone Acetonide | 653 | $4,819 |
| Mycophenolate Mofetil | 31 | $4,228 |
| Metronidazole | 82 | $3,425 |
| Betamethasone Dipropionate | 50 | $2,887 |
| Ketoconazole | 165 | $2,776 |
| Fluocinonide | 95 | $2,678 |
| Tretinoin | 32 | $2,261 |
| Tacrolimus | 29 | $2,238 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Grand Rapids
- Kurt AshackGrand Rapids$207K
- David OberlinGrand Rapids$103K
- Stephen CahillGrand Rapids$15K
- Johann GudjonssonAnn Arbor$15.9M
- Ali MoiinTroy$9.9M
- Linda Stein GoldWest Bloomfield$7.5M
- Wendy McFaldaClarkston$3.6M
- Kristi HawleyCaledonia$2.5M
- Brent BoyceSebewaing$2.2M
- David AltmanWarren$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.